Christopher Liu
Stock Analyst at Lucid Capital
(3.78)
# 1,932
Out of 5,000 analysts
150
Total ratings
42.3%
Success rate
8.4%
Average return
Main Sectors:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVCT Nuvectis Pharma | Reiterated: Buy | $22 → $34 | $21.70 | +56.68% | 3 | Aug 5, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Buy | $14 → $4 | $1.28 | +212.50% | 2 | Jun 5, 2026 | |
| NXTC NextCure | Reiterated: Buy | $25 | $5.28 | +373.48% | 2 | Jun 2, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $50 | $29.05 | +72.12% | 1 | May 28, 2026 | |
| ACTU Actuate Therapeutics | Reiterated: Buy | $5 | $0.62 | +706.45% | 1 | May 18, 2026 | |
| RLMD Relmada Therapeutics | Initiated Coverage: Buy | $14 | $3.81 | +267.45% | 1 | Mar 2, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $42 → $6 | $1.06 | +466.04% | 2 | Feb 4, 2026 | |
| ANL Adlai Nortye Group | Initiated Coverage: Buy | $11 | $15.86 | -30.64% | 1 | Jan 29, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $50 | $15.23 | +228.30% | 1 | Dec 15, 2025 | |
| IPHA Innate Pharma | Initiated Coverage: Buy | $8 | $1.71 | +367.84% | 1 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $10.12 | n/a | 1 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $2.98 | n/a | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $2.43 | n/a | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $1.45 | n/a | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $19 → $37 | $57.95 | n/a | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 → $36 | $23.65 | n/a | 20 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $2.50 | n/a | 1 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $36.74 | n/a | 7 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $31.43 | n/a | 28 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $17.73 | n/a | 4 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.03 | n/a | 14 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $77 | $7.79 | n/a | 22 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $11.72 | n/a | 12 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $13 | $11.26 | n/a | 2 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $27 | $4.98 | n/a | 2 | Aug 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.29 | n/a | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.56 | n/a | 2 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $14.68 | n/a | 2 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.85 | n/a | 1 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.0112 | n/a | 2 | Jul 6, 2018 |
Nuvectis Pharma
Aug 5, 2026
Reiterated: Buy
Price Target: $22 → $34
Current: $21.70
Upside: +56.68%
Cardiff Oncology
Jun 5, 2026
Reiterated: Buy
Price Target: $14 → $4
Current: $1.28
Upside: +212.50%
NextCure
Jun 2, 2026
Reiterated: Buy
Price Target: $25
Current: $5.28
Upside: +373.48%
Faeth Therapeutics
May 28, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $29.05
Upside: +72.12%
Actuate Therapeutics
May 18, 2026
Reiterated: Buy
Price Target: $5
Current: $0.62
Upside: +706.45%
Relmada Therapeutics
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $3.81
Upside: +267.45%
Tvardi Therapeutics
Feb 4, 2026
Upgraded: Buy
Price Target: $42 → $6
Current: $1.06
Upside: +466.04%
Adlai Nortye Group
Jan 29, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $15.86
Upside: -30.64%
Ascentage Pharma Group International
Dec 15, 2025
Initiated Coverage: Buy
Price Target: $50
Current: $15.23
Upside: +228.30%
Innate Pharma
Oct 23, 2025
Initiated Coverage: Buy
Price Target: $8
Current: $1.71
Upside: +367.84%
Sep 26, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $10.12
Upside: n/a
Sep 18, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $2.98
Upside: n/a
Jul 21, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $2.43
Upside: n/a
May 28, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $1.45
Upside: n/a
May 14, 2025
Reiterated: Hold
Price Target: $19 → $37
Current: $57.95
Upside: n/a
Apr 9, 2025
Reiterated: Buy
Price Target: $28 → $36
Current: $23.65
Upside: n/a
Jan 27, 2025
Reiterated: Buy
Price Target: $20
Current: $2.50
Upside: n/a
Feb 21, 2024
Reiterated: Buy
Price Target: $50
Current: $36.74
Upside: n/a
Feb 20, 2024
Reiterated: Buy
Price Target: n/a
Current: $31.43
Upside: n/a
Feb 13, 2024
Reiterated: Buy
Price Target: $18
Current: $17.73
Upside: n/a
Dec 13, 2023
Reiterated: Buy
Price Target: $14
Current: $3.03
Upside: n/a
Dec 8, 2023
Reiterated: Buy
Price Target: $70 → $77
Current: $7.79
Upside: n/a
Nov 9, 2023
Reiterated: Hold
Price Target: $5
Current: $11.72
Upside: n/a
Aug 9, 2018
Rated: Buy
Price Target: $13
Current: $11.26
Upside: n/a
Aug 2, 2018
Rated: Buy
Price Target: $27
Current: $4.98
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $0.29
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $25.56
Upside: n/a
Jul 6, 2018
Reiterated: Hold
Price Target: n/a
Current: $14.68
Upside: n/a
Jul 6, 2018
Reiterated: Hold
Price Target: n/a
Current: $0.85
Upside: n/a
Jul 6, 2018
Reiterated: Hold
Price Target: n/a
Current: $0.0112
Upside: n/a